Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

NCT01444807 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: sorafenib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano